16 June 2026
In plain English
Quiet day. The FDA's peptide advisory panel meets in 37 days and still has only three members seated out of twelve authorized — 29 weeks without an appointment, the longest vacancy streak Ra has tracked. The panel's oral presentation deadline and the close of public comments on banning large-scale compounding of weight-loss drugs like Ozempic (called GLP-1s) both fall on June 29–30, creating a two-day window where the compounding industry's attention will be maximally split.
Medicare's new $50-per-month weight-loss drug program launches July 1 — 15 days away. The application form, provider guidance, and consumer guides are all live. No enrollment data until after launch.
Separately, OneTwenty — a startup selling experimental drugs called peptides (short protein fragments used for recovery and longevity) — has now operated five weeks with zero FDA enforcement, past the 30-day threshold that signals regulatory forbearance.
Signal detail
37 days to PCAC. Roster unchanged: 3 voting members of 12 authorized. Oral presentation deadline June 30 (14 days). 503B exclusion comment period closes June 29. Historian: 29-week vacancy non-appointment is now the strongest absence signal in Ra's tracking history. Skeptic: counter-narrative (Kennedy batch-fills) requires action in a domain with zero demonstrated interest for half a year. Bayesian: no new evidence, posterior holds. Augur: 503B/PCAC calendar collision may generate coordinated industry messaging linking 503B GLP-1 closure to 503A peptide opening. Pre-commitment to adjust toward 0.50 if vacancies unfilled by June 30.
Same vacancy dynamics. Binary-outcome structural concern persists: 3-member panel favors all-pass or all-defer over 2-of-4 moderate outcomes. Same June 30 checkpoint pre-commitment.
Month 18 post-facility-acquisition — lower bound of 18–24mo base rate. OneTwenty 5+ weeks live, zero FDA enforcement. Hims CEO Pat Carroll publicly applauded FDA's peptide regulatory direction. Seeking Alpha analyst piece frames PCAC as "big moment" for Hims stock. No launch announcement. Next catalyst: PCAC July 23, then Q2 earnings August.
No new adverse events. Post-ADA / pre-PCAC media window Day 9 of 44. DOJ enforcement infrastructure intact. Lilly contamination template established. 287 days to resolution.
T-15 checkpoint executed yesterday (+0.02 to 0.75). CMS provider guidance page now live alongside beneficiary page and AMCP FAQ. Awareness infrastructure mature. No enrollment data until post-launch. Next reassessment: early July post-launch.
No peptide DTC affiliate programs. First-party: Katalys clicks +64% WoW (318), 1 SkinnyRx conversion ($500). GSC impressions -65% (1,041), but CTR improved to 1.83% and avg position to 17.4. Twelfth consecutive Google decline week, but Katalys click recovery suggests non-Google traffic channels are holding. CagriSema PDUFA late 2026 and retatrutide NDA expected add branded GLP-1 molecules. CPA math ($260–$500 vs $8–40) structural.
How Barque got smarter today
- Post-checkpoint stability. Yesterday's T-15 medicare checkpoint moved +0.02 to 0.75. Today's run confirms no further movement — the checkpoint executed cleanly with proportionate adjustment. Pre-commitment discipline working as designed.
- First-party divergence worth watching. Katalys clicks +64% WoW while GSC impressions -65% signals that glp1picks traffic is migrating to non-Google channels (AI referral, direct, social). The affiliate revenue model may decouple from Google organic sooner than expected. This pattern — if it persists — has implications for SEO-first product strategy across the portfolio.
- OneTwenty 5-week mark is a regulatory milestone. Five weeks of commercial peptide sales without FDA enforcement creates a reference-class data point for Hims launch timing. The longer OneTwenty operates unimpeded, the stronger the revealed-preference signal that FDA is deferring enforcement to the PCAC framework rather than pre-empting it.